



Communication

Comparative Analysis of Chromatin-Delivered Biomarkers in the Monitoring of Sepsis and Septic Shock: A Pilot Study

Jesús Beltrán-García ^{1,2,3,†}, Juan J. Manclús ^{4,†}, Eva M. García-López ^{1,3,5}, Nieves Carbonell ^{2,6}, José Ferreres ^{2,6}, María Rodríguez-Gimillo ^{2,6}, Concepción Garcés ¹, Federico V. Pallardó ^{1,2,3}, José L. García-Giménez ^{1,2,3,5}, Ángel Montoya ^{4,*} and Carlos Romá-Mateo ^{1,2,3,*}

- ¹ Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, 46010 Valencia, Spain; jesus.beltran@ext.uv.es (J.B.-G.); E.Maria.Garcia@uv.es (E.M.G.-L.); Concepcion.Garces@uv.es (C.G.); Federico.V.Pallardo@uv.es (F.V.P.); J.Luis.Garcia@uv.es (J.L.G.-G.);
- ² INCLIVA Biomedical Research Institute, 46010 Valencia, Spain; edurnecarbonell@yahoo.es (N.C.); ferreresj@gmail.com (J.F.); mariarodriguezgimillo@gmail.com (M.R.-G.)
- ³ Biomedical Research Networking Center of Rare Diseases (CIBERER), Institute of Health Carlos III, 28029 Madrid, Spain
- ⁴ Centro de Investigación e Innovación en Bioingeniería, Universitat Politècnica de València, 46022 Valencia, Spain; jmanclus@ci2b.upv.es
- ⁵ EpiDisease SL (Spin-Off Ciber-ISCIII), 46980 Paterna, Valencia, Spain
- ⁶ Intensive Care Unit, Clinical University Hospital of Valencia, 46010 Valencia, Spain
- * Correspondence: amontoya@ci2b.upv.es (Á.M.); carlos.roma@uv.es (C.R.-M.); Tel.: +34-96-387-7093 (Á.M.); +34-96-398-3170 (C.R.-M.)
- † These authors contributed equally to this work.

Citation: Beltrán-García, J.; Manclús, J.J.; García-López, E.M.; Carbonell, N.; Ferreres, J.; Rodríguez-Gimillo, M.; Garcés, C.; Pallardó, F.V.; García-Giménez, J.L.; Montoya, Á.; et al. Comparative Analysis of Chromatin-Delivered Biomarkers in the Monitoring of Sepsis and Septic Shock: A Pilot Study. *Int. J. Mol. Sci.* **2021**, *22*, 9935. <https://doi.org/10.3390/ijms22189935>

Academic Editor: Dumitru Constantin-Teodosiu

Received: 29 July 2021

Accepted: 11 September 2021

Published: 14 September 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).

Abstract: Sepsis management remains one of the most important challenges in modern clinical practice. Rapid progression from sepsis to septic shock is practically unpredictable, hence the critical need for sepsis biomarkers that can help clinicians in the management of patients to reduce the probability of a fatal outcome. Circulating nucleoproteins released during the inflammatory response to infection, including neutrophil extracellular traps, nucleosomes, and histones, and nuclear proteins like HMGB1, have been proposed as markers of disease progression since they are related to inflammation, oxidative stress, endothelial damage, and impairment of the coagulation response, among other pathological features. The aim of this work was to evaluate the actual potential for decision making/outcome prediction of the most commonly proposed chromatin-related biomarkers (i.e., nucleosomes, citrullinated H3, and HMGB1). To do this, we compared different ELISA measuring methods for quantifying plasma nucleoproteins in a cohort of critically ill patients diagnosed with sepsis or septic shock compared to nonseptic patients admitted to the intensive care unit (ICU), as well as to healthy subjects. Our results show that all studied biomarkers can be used to monitor sepsis progression, although they vary in their effectiveness to separate sepsis and septic shock patients. Our data suggest that HMGB1/citrullinated H3 determination in plasma is potentially the most promising clinical tool for the monitoring and stratification of septic patients.

Keywords: sepsis; septic shock; circulating histones; nucleosomes; HMGB1; biomarkers; ELISA

1. Introduction

Management of sepsis remains a worldwide challenge due to the difficulty in early recognition of symptoms to facilitate stratification and accurate/proper treatment of septic patients [1]. For instance, progression from sepsis to septic shock is currently unpredictable and depends on predisposing factors of the patient, the severity of the infection, and the response to therapy, as well as the degree of organ dysfunction. Thus, clinicians face a complex diagnostic landscape in which early, quick, and efficient intervention remains a critical necessity.

In this regard, the detailed study of the complex molecular abnormalities underlying sepsis might provide interesting and promising molecular candidates to be used as sepsis progression biomarkers that can help define the process of septic staging, which is currently considered a clinical demand at intensive care units (ICUs). Inflammatory response-related molecules secreted in response to pathogens, together with the molecules and signaling cascades related to the immune system and coagulation factor activation, interact with the host's cells to configure a complex network of molecules populating the blood of patients, which have been designated as pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Among the latter, we find nuclear elements released to the bloodstream in different ways: first, as part of the process known as NETosis, the formation of neutrophil extracellular traps (NETs), wherein neutrophils release a mesh of altered chromatin and nuclear proteins during the innate immune response, which opsonizes and compromises pathogenic cell viability. Nuclear elements released from NETs affect neighboring cells, promoting endothelial cell necrosis and apoptosis and, hence, increasing the release of more nuclear content to the bloodstream via a second pathway which, in the end, leads to a positive feedback process that establishes a correlation between the increase in the release of nuclear content and disease progression. Given the tight relationship that exists between the production of free radicals and the generation of oxidative stress resulting from endothelial cell dysfunction, especially in the context of sepsis progression, focusing on the molecular features of nuclear elements released to the bloodstream is a source of substantial potential clinical interest [2]. Nuclear factors typically found in the bloodstream of sepsis patients include free DNA, mono-, di-, and oligo-nucleosomes, and free histone proteins, among other chromatin-derived elements; thus, these factors are acquiring increasing relevance as DAMPs. This has given rise to a rich field of research into the definition disease biomarkers [3–9]; however, the lack of performance when using any of these molecules on their own to discriminate between sepsis and other inflammation-related pathologies highlights the necessity of new and more specific biomarkers, which should also be preferentially used in combination [10]. The release of nuclear content has been documented as part of the inflammatory NETosis response and as a result of organ injury during sepsis progression [8,11]. In summary, histone proteins, either in form of NETs, nucleosomes, or as individual proteins, are responsible for endothelial cell damage by means of several transduction pathways which are not fully understood [12–16]. The cell death consequences of the presence of histones in blood suggest that they could be used as disease progression biomarkers [17,18]. In this regard, there is also evidence for the participation of another nuclear protein, High-Mobility Group Box-1 (HMGB1), as part of the cytokine storm triggered during the inflammatory response to infection [19]. HMGB1 contributes to the pro-inflammatory state, and several works have shown that extracellular HMGB1 levels correlate with disease progression and participate in cell death processes tightly linked to pyroptosis and endotoxemia [20]; however, many details regarding the specific kinetics of its release and clearance from the bloodstream are still partly unknown. Since HMGB1 can be found in differentially oxidized forms and has been reported to influence the activity of endothelial eNOS and ROS pathways [21], studying its presence in the bloodstreams of sepsis patients in relation to the impairment of clinical parameters could provide important clues regarding the regulation of antioxidant response homeostasis and sepsis progression.

Correlations between blood levels of nucleoproteins and disease severity [17,22,23] set the basis for detecting their circulating levels in the blood as a parameter that could predict the onset of sepsis in patients. Several detection methods to measure circulating histones, nucleosomes, and nucleoproteins have been developed in order to use these parameters as effective, time-saving biomarkers that could avoid the striking consequences of permanent histone levels in the blood or that could, at least, differentiate between those patients that should receive more aggressive treatments or earlier fluid resuscitation in order to avoid a fatal outcome. Most widely used methodologies involve immunoassays,

generally in the form of enzyme-linked immunosorbent assay (herein, ELISA) kits. For example, one of the most used kits for the evaluation of circulating chromatin-derived molecules, Cell Death detection ELISAPLUS kit (Roche), consists of the detection of mono- and oligo-nucleosomes, but not cell-free circulating histones. Another similar parameter for which immunoassays have been developed is citrullinated histone H3, a specific post-translational modification that has been related to the correct and appropriate production of NETs during the innate immunity response as well as in the particular context of sepsis [24].

In the present work, we sought to evaluate the actual potential for decision making/outcome prediction of the most commonly proposed chromatin-related biomarkers (i.e., nucleosomes, citrullinated H3, and HMGB1) in a pilot study to differentiate between sepsis and septic shock patients in reference to controls, which included both healthy subjects and, importantly, critically ill nonseptic patients from the ICU who had suffered spontaneous intracerebral hemorrhage. To do so, we compare the results of quantification of these biomarkers obtained using different ELISA methods, including our own home-made nucleoprotein-detection ELISA kit, and analyzed the capacity of the different methods to discriminate between groups. Finally, we provide a series of correlation analyses between the aforementioned biomarkers and clinical parameters relevant to the monitoring sepsis and septic shock progression, emphasizing the use of specific chromatin-derived biomarkers for the particular subtypes of septic patients analyzed herein.

2. Results

2.1. Development of a Home-Made Immunoassay for Detection of Nucleoproteins in Plasma

In order to evaluate the potential of nucleoprotein detection in plasma as a sepsis biomarker, a home-made enzyme-linked immunosorbent assay (ELISA) based on monoclonal antibodies was developed. To this end, spleen cells from MRL-lpr/lpr mice that spontaneously produced antinucleoprotein antibodies were used to obtain monoclonal antibodies by applying the hybridoma technology. After fusions, clone selection was based on recognition of histone complexes as a protein core or as nucleosomes isolated from HeLa cells. Finally, 12 hybridomas were cloned and stabilized. Their corresponding monoclonal antibodies (MAb) were assayed for specificity towards HeLa nucleoproteins. Approximately half of the MAbs recognized both core histones and nucleosomes, while the other half were highly specific for nucleosomes. Next, MAbs displaying the highest titers for nucleoproteins were conjugated to peroxidase. After a thorough MAb examination in a sandwich ELISA format, a pair of MAbs showing high specificity to nucleosomes was selected for the immunoassay. The specificity of capture MAb L1-4 and detection MAb L2.14 is shown in Figure 1. As shown, the capture antibody recognized core histones, whereas the detection antibody was specific for nucleosomes. Next, immunoassay conditions such as immunoreagent concentrations, incubation times, and assay buffer were optimized. Finally, the optimized ELISA was evaluated in terms of sensitivity and reproducibility. A limit of detection (LOD) of 20 ng nucleosomes/ml was obtained (see Appendix A), with intra- and interassay coefficients of variation below 10%. As expected, the ELISA recognition pattern was that provided by the detection antibody (MAb L2-14), characterized by the specific recognition of nucleosomes and the lack of recognition of different combinations of histones, complex histone extracts, and DNA from different sources (Figure 1b). These results prompted us to test the kit using plasma samples from ICU patients, including patients with intracerebral hemorrhage (critically ill patients without sepsis), sepsis and septic shock patients, and healthy subjects, to validate the potential use of the tool for sepsis and septic shock progression monitoring.




Figure 1. Specificity patterns of the monoclonal antibodies selected for the nucleoprotein sandwich ELISA. **(a)** The MAb L1–4 capture antibody recognized all histone fractions from human origin. **(b)** In contrast, the MAb L2–14 detection antibody showed a reaction only to HeLa nucleosomes (BPS Bioscience). Data represent mean values \pm SD ($n = 2$). H1, H1.0, H2A, H2B, H3, and HeLa core correspond to histones from human origin; DNA to calf thymus DNA; BSA-Met to albumin methylated from bovine serum; and OVA to albumin from chicken egg. See Appendix A for more details on the proteins assayed.

2.2. Analysis of Nucleoprotein Levels in a Cohort of Sepsis and Septic Shock Patients


Fifty-three samples of blood from subjects of four different groups were analyzed using two different ELISA kits, as described in the Methods section. Clinical characteristics of the three groups of clinically ill subjects are described in Table 1. In general, the most significant clinical differences in Table 1 were found between control nonseptic patients and septic shock patients in all standard parameters. The measurements with statistically significant differences among groups were C-reactive protein ($p > 0.0001$), activated partial thromboplastin time (APTT) ($p = 0.014$), and the clinical APACHE II and SOFA scores ($p > 0.03$ and $p < 0.001$, respectively). It was noteworthy that mortality and ICU stay, and other classical biochemical biomarkers (i.e., lactate and PCT) did not show statistically significant differences between sepsis and septic shock patients. Interestingly, in the case of circulating nucleoproteins, the highest plasma levels were found in the septic shock group, followed by the sepsis group, when samples were analyzed utilizing both our home-made immunoassay (hereafter, Nucleosome kit 1) and the commercial Cell Death detection kit (Roche) (hereafter, Nucleosome kit 2) (Figure 2).

In order to compare the levels observed in the different groups, we performed non-parametric Kruskal–Wallis tests. For the Nucleosome kit 1, the differences between groups were statistically significant only between both control groups and septic shock patients ($p < 0.01$) (Figure 2a); the Nucleosome kit 2 differentiated healthy and septic shock subjects with the same statistical strength, but it reached greater statistical significance when separating healthy subjects and septic shock patients ($p < 0.0001$).

Table 1. Baseline clinical features of the septic patients and ICU controls at admission ¹.

	Control Nonseptic ICU (n = 9)	Septic ICU (n = 10)	Septic Shock ICU (n = 17)	p Value
Demographics and clinical indexes				
Age (years) (mean ± SD)	64.38 ± 8.31	65.10 ± 13.10	66.18 ± 11.60	ns
Male gender (%)	6 (66.7)	7 (70.8)	10 (58.8)	ns
APACHE II score (mean ± SD)	15.11 ± 4.80	15.80 ± 4.90	22.12 ± 9.07	0.03
SOFA (mean ± SD)	3.44 ± 3.09	5.00 ± 2.21	9.65 ± 3.43	< 0.0001
Organ support therapy (1st day)				
Vasopressor therapy (%)	1 (11.1)	2 (20.0)	16 (94.1)	<0.0001
CRRT (%)	0	0	2 (11.76)	ns
Mechanical ventilation (%)	3 (33.3)	0	3 (21.4)	ns
Inflammatory parameters				
White blood cells (mean ± SD)	10,603 ± 4939	12,977 ± 11,589	16,395 ± 9612	ns
CRP (mg/l) (mean ± SD)	25.14 ± 26.31	250.20 ± 133.46	339.35 ± 189.72	< 0.0001
PCT (ng/ml) (mean ± SD)	0.06 ± 0.07	2.21 ± 3.08	1.52 ± 2.29	ns
Lactate				
Lactate 1st hour (mmol/l) (mean ± SD)	1.61 ± 6.98	1.91 ± 1.25	1.81 ± 1.99	ns
Coagulopathy parameters				
Platelets count/l (mean ± SD)	240.4 × 10 ³ ± 89.3 × 10 ³	229.6 × 10 ³ ± 147.36 × 10 ³	169.4 × 10 ³ ± 122.8 × 10 ³	n.s
APTT (seconds) (mean ± SD)	29.67 ± 2.88	99.833 ± 118.82	117.43 ± 154.83	0.014
Outcome				
ICU LOS (days) (mean ± SD)	5.9 ± 6.6	12.6 ± 15.62	9.47 ± 8.61	ns
Hospital LOS (days) (mean ± SD)	15.4 ± 14.6	20.6 ± 13.1	19.88 ± 17.8	ns
ICU Mortality (%)	2 (22.2)	2 (20.0)	4 (23.5)	ns

¹ ICU: intensive care unit. APACHEII: Acute Physiology and Chronic Health Evaluation score during the 1st day of ICU admittance. SOFA score: Sequential Organ Failure Assessment score during the 1st day of ICU admittance. CRRT: continuous renal replacement therapy. CRP: C-reactive protein. PCT: procalcitonin. APTT: activated partial thromboplastin time. LOS: length of stay. Significant differences (p value < 0.05) between groups.

**Figure 2.** Measurement of nucleoproteins using ELISA kits. Plasma samples were analyzed using a home-made ELISA kit, Nucleosome kit 1 (a) and a commercial ELISA kit (Cell Death Detection

ELISAPLUS kit; see Methods), Nucleosome kit 2 (b) specific for mono- and oligo-nucleosomes. Horizontal lines represent average values for each group, and bars represent standard deviation. Numerical values are summarized in (c). (**** $p < 0.0001$; ** $p > 0.01$).

2.3. Citrullinated Histone H3 and HMGB1 Levels in Sepsis and Septic Shock Patients

Among the PAMPs and DAMPs associated with the challenging septic response, citrullinated histone H3 and HMGB1 have been suggested as potential sepsis biomarkers. Hence, we decided to use a second set of commercial kits for the determination of these molecules in the same samples from the four cohorts. As found with the other kits used in this work, the highest citrullinated H3 levels were observed for septic shock cases (Figure 3a). Differences were statistically significant between healthy subjects and ICU controls and septic shock ($p < 0.0001$), and between healthy subjects and ICU controls and sepsis ($p < 0.05$). Regarding determination of HMGB1 levels, and in contrast to the previous results, these were not significantly higher exclusively in septic shock patients; in fact, significance between healthy subjects and sepsis was higher than between healthy subjects and septic shock patients ($p < 0.0001$ vs. $p < 0.001$); when comparing ICU controls and both groups of patients, again the highest statistical significance was found between ICU controls and sepsis patients ($p < 0.001$). In contrast, ICU controls and septic shock patients were differentiated with $p < 0.01$ (Figure 3b). It should be noted that although all previously analyzed molecules exhibited the highest levels in the group of septic shock patients, in the case of HMGB1, the levels were comparable in sepsis and septic shock patients, and it was the only case in which the mean value was higher in the sepsis group as compared to the septic shock group (Figure 3c).





Figure 3. Measurement of citrullinated histone H3 levels (CitH3) (a) and HMGB1 (b) in plasma samples using commercial ELISA kits (see Materials and Methods for details). Horizontal lines represent the average values for each group, and bars represent standard deviation. Numerical values for both parameters are summarized in (c) (**** $p > 0.0001$; *** $p < 0.001$; ** $p > 0.01$; * $p < 0.005$).

2.4. Comparative Analysis of the Diagnostic Potential of Chromatin-Delivered Biomarkers

In order to further compare the different ELISA methods, a ROC curve analysis was performed to evaluate the diagnostic power of the levels of nuclear proteins and citrullinated histone H3 as relevant biomarkers to distinguish septic shock or sepsis cases from

critically ill ICU patients suffering not from infectious processes, but from spontaneous intracerebral hemorrhage (Figure 4). The AUCs (areas under ROC curves), standard error, confidence interval (CI), optimal concentration cut-off value, and sensitivity and specificity percentages for each kit were calculated to differentiate between controls and cases (sepsis and septic shock patients together) (see table in Figure 4b). Interestingly, levels of HMGB1 stood out with a 100.0% sensitivity and 90.0% specificity to differentiate between control and case groups, indicating that the presence of HMGB1 is a reliable biomarker for the septic state as compared to critically ill noninfected individuals from ICU, and thus supporting its use as an early marker of sepsis. Citrullinated histone H3 also provided a good sensitivity (81.5%) and as much specificity (100.0%) as the nucleosome-based detection methods, although the latter failed in terms of sensitivity, which was below 80% for both nucleosome kits. It should be pointed out that the highest statistical confidence was found for citrullinated histone H3 and HMGB1 ($p < 0.0001$).

(a)



(b)

Kit	AUC	Standard error	CI 95%	p value	Cut off value	Sensitivity (%)	Specificity (%)
Nucleosomekit 1	0.877	0.061	0.758-0.996	0.0008	110.8	66.7	100.0
Nucleosomekit 2	0.864	0.060	0.746-0.982	0.0012	0.09	77.8	100.0
Citrullinated H3	0.949	0.035	0.880-1.000	<0.0001	9.82	81.5	100.0
HMGB1	0.996	0.006	0.984-1.000	<0.0001	1.73	100.0	90.0

Figure 4. Diagnostic capacity of ELISA methods to differentiate control and septic cases. (a) ROC curves for nucleoproteins, HMGB1, and citrullinated H3 levels, measured using the three different ELISA approaches, as biomarkers for diagnosis of septic processes. ICU controls were compared to septic patients (sepsis patients plus septic shock patients). (b) Parameters and statistical significance obtained for the different ROC curves.

2.5. Correlation with Clinical Parameters in Sepsis Patients Varies between Nucleosomes, Citrullinated Histone H3, and HMGB1

Extracellular histones have been previously related to sepsis progression and organ failure, specifically linked to proinflammatory and prothrombotic effects [18,25–27]. It has also been suggested that HMGB1 could be used as a late marker of sepsis [28], although our results showed increased levels of HMGB1 not only in septic shock but in sepsis patients. In order to extract as much information as possible about the differential behaviors of chromatin-delivered biomarkers during sepsis progression, we calculated the correla-

tion coefficients between each of the biomarkers in our study and clinically relevant parameters of the studied cohorts (see Supplementary Table S1 for a complete correlation matrix). The higher number of correlations was found among the group of sepsis patients (Figure 5). Interestingly, the pattern of positive and negative correlations was relatively similar for both nucleosome-specific kits and the CitH3 kit, and slightly different from the pattern observed for HMGB1. When analyzing the specific significance of these correlations, differences were highlighted among all kits, providing specific positive and negative correlations: we found very strong correlations between CitH3, total SOFA score, and MAP; and between HMGB1 and other important clinical parameters like ICU LOS and DD (Figure 5a). These results, taken together with the previous analysis of diagnostic capacity and mean values found in plasma from the different groups of patients, highlight that CitH3 and HMGB1 levels stand out as the most informative biomarkers in terms of stage of the sepsis process and relevant clinical parameters related to sepsis management, with CitH3 being a potential better biomarker for the diagnostic of septic shock and HMGB1 a more prognostic one; in fact, we generated ROC curves to evaluate the predictive potential of HMGB1 levels for ICU stays longer than 5 days, obtaining an AUC value of 0.9583 and a specificity and sensitivity of 83.33% and 100%, respectively, for levels higher than 15.27 ng/ in sepsis, but no significant cut-off value was obtained for its use as a reliable predictor in the group of septic shock patients (Figure 5b). Finally, it was noteworthy that the only biomarker significantly increased in the specific subset of nonsurviving patients was citrullinated H3 (14.11 ng/ in surviving patients versus 19.00 ng/ in nonsurvivors; $p = 0.03$); this allowed us to create a ROC curve using citrullinated H3 level as a criterion to differentiate surviving sepsis and septic shock patients from those nonsurviving, obtaining an AUC of 0.897 with a standard error of 0.062, a CI95% of 0.7745 to 1.000, and sensitivity and specificity values of 83.3% and 81.0%, respectively, using a cut-off value of 14.81 ng/ (p value = 0.003) (Figure 5c).




Figure 5. (a) Correlation between biomarker levels measured using the different ELISA kits and clinical parameters. Nonparametric Spearman correlation coefficients were calculated among the different variables: blue cells represent positive correlations and red cells represent negative correlations (see graphic legend); white dots indicate r values higher than 0.6, which reached the minimum significance ($p \leq 0.05$). The top correlations most significant for CitH3 and HMGB1 are shown in detail. ICU LOS: ICU length-of-stay; SOFA: total SOFA score; SAP: systolic arterial pressure; MAP: mean arterial pressure; RF: respiratory frequency; AP: alkaline phosphatase; BIL: total bilirubin; GLUC: glucose; aPTT: activated partial thromboplastin time; Fibrin: fibrinogen; DD: D-dimer; NtProBNP: amino-terminal fragment of the pro-natriuretic peptide type B. All clinical parameters represent values at day 1. See Supplementary Table S1 for detail on the complete r and p values for each correlation. (b) ROC curves obtained using HMGB1 levels to predict ICU stays longer than 5 days in sepsis (left) and septic shock patients (right). (c) ROC curve obtained using CitH3 levels to predict fatal outcomes for sepsis and septic shock patients.

3. Discussion

Sepsis management remains a worldwide critical healthcare problem, despite striking advances in diagnostic and pharmacological interventions that have lowered the incidence during the last twenty years [29]. Nonetheless, deaths by sepsis are usually underestimated given the high burden of the disease in low-income countries, where documentation of cases remains uncertain or incomplete. In this particular context, the capacity to distinguish the cryptic first signs of septic processes from other conditions and, significantly, to predict if a septic process is on the verge of becoming a septic shock, constitutes

a hotspot in the clinical management of the critically ill patient. The presence of extracellular nucleoproteins, either as free histones or in the form of nucleosomes, has been shown to correlate with disease severity and to participate actively in the pathogenicity, being critical determinants of organ failure and hence indicators of bad prognosis [25,30]. The use of histone-based biomarkers, however, has never been standardized and incorporated into clinical routine, although novel methods based either in immunological detection [15,25] or in mass-spectrometry detection, as we have previously published [22], are currently available [31].

In this work, we evaluated the potential of several markers based on different chromatin-delivered analytes to differentiate sepsis and septic shock patients, compared to healthy individuals and critically ill nonseptic control patients from ICU. One of the immunoassays most commonly found in the literature is the Cell Death Detection ELISAplus, previously used to assess nucleosome levels in critically ill patients [23,30]. However, this kit does not provide a standard curve to obtain objective quantification of plasma circulating nucleoproteins, unlike our home-made ELISA kit with high specificity towards human nucleosomes. Nonetheless, neither of both tests showed the capacity to differentiate between sepsis and septic shock patients. Similarly, we detected significantly higher CitH3 levels in septic shock patients as compared to both control groups; this is of especial relevance since a previous work by Li et al. identified high blood levels of citrullinated H3 after lipopolysaccharide injection in a rodent model to produce septic shock [24]. Interestingly, when we measured the protein HMGB1 in human plasma, we found the maximum increase in the group of sepsis patients. Although no statistical significance was found between sepsis and septic shock patients, mean values were higher in the sepsis group. HMGB1, released to the bloodstream during the initial inflammatory cascade, has been postulated as a pro-inflammatory cytokine that could serve as an early biomarker in sepsis. However, its differential functions regarding oxidation status, cellular localization, and release to the bloodstream make it a difficult target for therapeutic intervention [20,28]. To assess the feasibility of the methods herein assayed for use with diagnostic or prognostic objectives, we performed ROC curve analysis to obtain specificity and sensitivity values for all ELISA kits. The test which showed the best performance to differentiate all control individuals from sepsis and septic shock patients was the analysis of HMGB1, with a specificity of 81.8% and a sensitivity of 96.0%, in agreement with the highest levels found in both groups of patients as compared to the rest of biomarkers assayed. These results are interesting given that the groups of clinically ill patients did not differ strikingly in the levels of classical sepsis biomarkers like lactate or PCT, and the fact that mortality rates were also quite similar. However, diagnostic and/or prognostic potential of biomarkers relies strongly upon the correlation between their levels and the different clinical parameters that allow monitoring of disease progression and severity; in our study, we found a strong correlation between all chromatin-delivered biomarkers and relevant clinical parameters, but especially important are those high and significant correlations found between CitH3, total SOFA score, and MAP, and between HMGB1, ICU LOS, and DD. Previous works support the relationship between HMGB1 levels and cardiovascular impairment [32–34]. It is interesting to point out that the levels detected in our results were significantly higher in septic patients even when using the group of ICU patients suffering from spontaneous intracerebral hemorrhage as a control group. It is noteworthy that HMGB1 has been shown to be present in differentially oxidized and reduced forms [21,28], but little information has been provided regarding the inflammatory properties of the different forms when found in the extracellular milieu and in the context of sepsis progression, where oxidation conditions are significantly increased; thus, further investigation will be required to ascertain the usefulness of the analysis of specific forms of HMGB1 as well as the therapeutic potential of antioxidant therapies in mitigating the deleterious effects associated with increased plasma levels of HMGB1. Although the correlation between HMGB1 levels and sepsis progression is not novel in itself, as shown by Karlsson and collaborators [35], there have been very few works, to our knowledge, that

compare the levels of this biomarker among patients classified according to the latest SEP-SIS-3 diagnostic criteria (i.e., sepsis vs. septic shock) and, importantly, compared to both healthy individuals and noninfected ICU patients. In our work, plasma samples were collected from patients at 24 h after ICU admittance, in contrast to the cohort analyzed in [35] which were collected at 48 h post-admission, probably explaining the lack of correlation of HMGB1 with the outcome in their results. Finally, our work compared in parallel the levels of three different types of chromatin-related biomarkers.

Taken together, these results seem to suggest that the kinetics of release and presence in the bloodstream for HMGB1 and histone-related molecules (i.e., nucleosomes and citrullinated H3) are different, and point to a landscape in which monitoring of HMGB1 levels is more useful for earlier stages of sepsis diagnosis and to predict long ICU stays, whereas increased levels of CitH3 would be more reliable for monitoring and prediction of septic shock onset, organ failure, and death. It should be noted that, given the limitations of our work (reduced sample number), the actual values of circulating histones and nucleoproteins should be further calculated with more quantitative techniques; in this regard, mass-spectrometry-based technologies constitute a promising path to follow, as we previously proposed [22]. However, the present results point to a relevant usefulness of the measurement of CitH3 and HMGB1 by ELISA methods, which are more accessible to low-income facilities, which could also benefit from home-made immunoassays addressed to detect nucleoproteins, as we have shown.

In conclusion, these results suggest that all biomarkers analyzed show a very similar distribution pattern, with HMGB1 showing the highest levels in sepsis patients as compared to septic shock ones. All in all, the presence of nucleosomes and specific modified forms of histone proteins together with other chromatin-derived nuclear proteins involved in inflammation rise as relevant markers of disease severity, and refinement of their detection and quantification methods would be of capital relevance towards their future incorporation into the clinical routine.

4. Materials and Methods

4.1. Production of Monoclonal Antinucleoprotein Antibodies

MRL-lpr/lpr female mice (9 weeks old) were from Harlan Laboratories. These mice spontaneously develop an autoimmune disease characterized by circulating antinuclear antibodies and immune complex glomerulonephritis (see Supplemental Methods for details). Animal manipulation was carried out following the Spanish regulations currently in force and under the approval of the Ethical Committee for Research of Universitat Politècnica de València, and all methods were carried out according to their corresponding guidelines and regulations.

4.2. Home-Made Nucleosome ELISA

The immunoassay consisted of a sandwich format using MAb L1–4 as the capture antibody and MAb L2–14 as the detection antibody. For this purpose, MAb L2–14 was previously conjugated to peroxidase using the HRP Conjugation Kit (Abcam, Cambridge, UK), following the manufacturer's instructions. For the immunoassay, a volume of 100 µL per well was used for all assay steps. After each incubation time, plates were washed four times with washing buffer (PBS containing 0.05 Tween 20). First, ELISA plates (Costar #3590, Corning, NY, USA) were coated overnight at room temperature with MAb L1–4 at 2 µg/ in 50 mM carbonate buffer (pH 9.6). Next, plasma samples diluted 1:5 in assay buffer and controls were added and plates were incubated for 1 h. After washing, HRP-MAb L2–14 at 0.5 µg/ in assay buffer was added and incubated for 1 h. Finally, peroxidase activity was determined by adding the substrate solution (2 mg/ o-phenylenediamine and 0.012% H₂O₂ in 25 mM citrate-62 mM phosphate, pH 5.3). After 10 min, the reaction was stopped with 2.5 M sulfuric acid and the absorbance at 490 nm was read and recorded with a Spec-

traMax 190 microplate reader (Molecular Devices, San José, CA, USA). Proteins and combination of proteins plus DNA used to test the specificity of the ELISA are described in Supplemental Methods.

4.3. Commercial ELISA Kits

The commercial ELISA kits used in this work were as follows: Cell Death Detection ELISAPLUS kit (Roche, Basel, Switzerland) for photometric determination of mono- and oligonucleosomes by combining an anti-histone-biotin-antibody and an anti-DNA-peroxidase antibody; EpiQuick™ Circulating Histone H3 Citrullination ELISA kit (EpiGentek, Farmingdale, NY, USA), in which histone proteins contained in plasma samples are captured on strips coated with anticitrullinated histone H3 antibody, detected by colorimetry and quantified thanks to an internal standard curve; and HMGB1 ELISA (IBL International, Hamburg, Germany), with strips coated with anti-HMGB1 purified antibody, detected by colorimetry and quantified thanks to an internal standard curve. Assays were performed following manufacturers' instructions, using 20 µL of plasma (1/4 dilution) for the Cell Death Detection kit, 30 µL of plasma for the citrullinated H3 detection kit, and 70 µL of plasma for the HMGB1 detection kit. Read-outs of the plates was obtained by measuring absorbance at 405 nm and 450 nm, respectively, using a SpectraMax 190 microplate reader (Molecular Devices, San José, CA, USA).

4.4. Selection of the Cohorts and Blood Collection

To provide an accurate evaluation and comparison for the usefulness of the three studied ELISA kits in the classification of sepsis and septic shock patients, we selected a cohort of individuals ($n = 53$) divided into four different groups. All of the subjects participating in this project signed the informed consent form. The first group was of healthy subjects ($n = 17$), a group in which no significant presence of nucleoproteins in plasma should be expected, composed of 10 male and 7 female volunteers (age: 49.76 ± 5.18 years); next, a cohort of control nonseptic patients ($n = 9$) from the ICU of the Clinical University Hospital of Valencia (HCUV) who were not affected by infection, autoimmune disease, or polytrauma injury but by spontaneous intracerebral hemorrhage, were set as a control group in which a certain level of nucleoproteins, free DNA, and histones could be present due to organ injury. Finally, two different cohorts including sepsis ($n = 10$) and septic shock patients ($n = 17$) with confirmed bacteremia (microbiological blood positive culture at 48 h) were included, all from the same ICU as the previously mentioned control group (see Supplemental Methods for details on exclusion criteria).

Peripheral blood samples were collected using EDTA tubes from both healthy controls and ICU patients. In the latter, blood samples were collected within the first 6 h after being admitted to ICU. Each sample was centrifuged at 2500 rpm for 10 min at room temperature (RT) to separate plasma. Aliquots were then stored at -80 °C until analysis.

4.5. Statistical Analysis

Descriptive analysis was performed by calculating parameters such as mean, median, standard deviation, and confidence intervals. Kruskal–Wallis and post hoc tests were used for comparisons between groups. ROC analyses were performed by calculating AUCs (areas under ROC curves), standard error, confidence interval (CI), optimal concentration cut-off value, and sensitivity and specificity percentages for each kit with diagnostic and stratification purposes. p values of < 0.05 were regarded as being statistically significant. All the analyses were conducted using SPSS, v.24 (IBM Corporation, Armonk, NY, USA).

Supplementary Materials: The following are available online at www.mdpi.com/article/10.3390/ijms22189935/s1.

Author Contributions: J.B.-G. and J.J.M. contributed equally to this work. Study designed by: C.R.-M., A.M., J.B.-G., J.J.M., J.L.G.-G., N.C. and F.V.P. Study conducted by: J.B.-G., J.J.M., J.L.G.-G., C.R.-M., C.G., N.C., J.F. and M.R.-G. Clinical parameters and data collection by: N.C., J.F. and M.R.-G. Statistical analysis by: E.M.G.-L., N.C. and M.G.R.-G. Data interpretation and analysis by: C.R.-M., A.M., E.M.G.-L., J.L.G.-G., J.J.M., F.V.P., N.C. and J.F. Manuscript drafted by: C.R.-M., J.B.-G. and A.M. Manuscript content revised by: J.L.G.-G., F.V.P., N.C., J.F., E.M.G.-L. and J.J.M. All authors have read and agreed to the published version of the manuscript.

Funding: This activity received funding from the European Institute of Innovation and Technology (EIT). This body of the European Union receives support from the European Union's Horizon 2020 research and innovation program. C.R.-M. thanks GVA for starting grant (GV/2018/127) and Spanish Ministry of Science and Innovation for research project (PID2020-119127RA-I00); J.B.-G. thanks ISCIII, AES2018 for iPFIS fellowship (IFI18/00015) and GVA for APOTI fellowship (APOTIP/2017/012); CG thanks Spanish Ministry of Universities for fellowship FPU18/03969; J.L.G.-G. and F.V.P. thank INCLIVA, GVA and AES2016 and AES2019 (ISCIII) for starting grant (GV/2014/132), project PI16/01036 and PI19/00994 and project DTS17/00132 (co-financed by the ERDF). The project leading to these results has received funding from "la Caixa" Foundation (ID 100010434), under agreement CI18-0009. C.R.-M., F.V.P. and A.M. thank Grand Challenges Canada.

Institutional Review Board Statement: All the experimental protocols and methods were carried out after obtaining approval from the local Biomedical Research Ethics Committee of HCUV and performed according to the relevant guidelines and regulations following to the World Medical Association Declaration of Helsinki regarding the ethical conduct of research involving human subjects. Samples and data from patients included in this study were provided by the INCLIVA Biobank (PT20/0029; B.000768 ISCIII), integrated in the Spanish National Biobanks Network and in the Valencian Biobanking Network and they were processed following standard operating procedures with the appropriate approval of the Ethics and Scientific Committees.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study; all the experimental protocols and methods were carried out after obtaining approval from the local Biomedical Research Ethics Committee of HCUV and performed in accordance with the relevant guidelines and regulations in accordance with the World Medical Association Declaration of Helsinki regarding ethical conduct of research involving human subjects. Samples and data from patients included in this study were provided by the INCLIVA Biobank with the appropriate approval of the Ethical and Scientific Committees.

Acknowledgments: We want to particularly acknowledge the patients and the INCLIVA Biobank (PT17/0015/0049; B.000768 ISCIII) integrated in the Valencian Biobanking Network and the Spanish National Biobanks Network for their collaboration.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Appendix A

Appendix A.1. Purification and Isolation of Monoclonal Antibodies

Mouse plasmas were assayed for antinucleoprotein antibodies at two-week intervals by indirect ELISA. Briefly, ELISA plates were coated with native nucleosomes purified from human HeLa cells (BPS Bioscience) and histones isolated from HeLa cells (see next subsection). After adding plasma dilutions in assay buffer (PBS containing 0.05% Tween-20 and 5 mg/ BSA), peroxidase-labeled rabbit antimouse immunoglobulins (Dako) were used as detection antibodies at a 1:2000 dilution in assay buffer. Once a high titer of circulating antinucleoprotein antibodies was demonstrated (22 weeks), mice were used as spleen cell donors for fusions. MRL-lpr/lpr spleen cells were fused to the nonsecreting myeloma cell line P3-X63-Ag8.653 according to established protocols. One week after fusion, hybridoma culture supernatants were doubly screened by indirect ELISA with nucleosomes and histones from HeLa cells as antigens. Positive hybridomas for at least one antigen were subsequently cloned by limiting dilution. Stable antibody-producing clones

were expanded and cryopreserved in liquid nitrogen. Monoclonal antibodies were purified on a small scale directly from late-stationary-phase culture supernatants by affinity chromatography on a Hytrap protein G column (GE Healthcare). MAbs were characterized to select the most suitable for use as immunoreagents for subsequent immunoassay development.


Appendix A.2. Purification of Histones

Histones were purified from HeLa cells. Cells were grown in Dulbecco's modified Eagle medium, high glucose (Gibco), supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37 °C and 5% CO₂. After reaching confluence, cells were lysed using the acid extraction protocol previously described by Shechter et al. (1) Briefly, cell nuclei were isolated by hypotonic lysis in buffer containing 10 mM Tris-HCl, pH 8.0, 1 mM KCl, 1.5 mM MgCl₂, 1 mM dithiothreitol, 0.4 mM phenylmethylsulfonyl fluoride, 1 mM orthovanadate, and 1 µg/ of protease inhibitors (Roche Diagnostics) in constant rotation during 1 h. Afterwards, pelleted nuclei were acid-extracted using 0.4 N sulfuric acid overnight at 4 °C, precipitated with 99% trichloroacetic acid, washed with cold acetone, and resuspended in bi-distilled water. Protein concentration was calculated using the Bradford method. (2) Total histone extracts were further purified by Fast Protein Liquid Chromatography (FPLC) using the ÄKTATM Pure system and a SOURCETM 15RPC ST 4.6/100 reverse-phase chromatography column (GE Healthcare). Fractions were separated by acetonitrile–trifluoroacetic gradient, and enrichment in specific histone proteins was determined by SDS-PAGE, Coomassie staining, and Western blot. Antibodies used were anti-H1, anti-H2A (Cell Signalling), and anti-H3 (Merck Millipore).

Appendix A.3. Analytes Used in the Specificity Tests for Home-Made ELISA and Standard Curve

H1, H1.0, H2A, H2B, and H3 histone fractions were isolated from HeLa cells; Bovine H3: commercial purified histone H3 from bovine tissue (Mybiosource); Bovine Core: commercial histones purified from calf thymus (Sigma); HeLa Core: purified combination of total core histone proteins from HeLa cells; HeLa nucleosomes: purified nucleosomes obtained after treatment of nuclear chromatin extracts from HeLa cell cultures (see section Appendix A.3) with micrococcal nuclease (MNase); DNA was from calf thymus (Sigma); BSA-Met: albumin methylated from bovine serum (Sigma); OVA: albumin from chicken egg (Sigma).

A standard curve was prepared with increasing concentrations of nucleosomes purified from HeLa cells to test the sensitivity of the developed ELISA sandwich method; detection limit (LD) was defined as the analyte concentration that provides a signal which equals the signal of the blank plus four times the signal of the blank's standard deviation.



Appendix A.4. Exclusion Criteria for the Cohorts and Results for Hemoculture

The exclusion criteria for ICU controls and sepsis and septic shock cases were: (i) patients with a life expectancy under 24 h; (ii) patients beyond the age range of 18–85 years; (iii) patients with an active neoplastic process or treated with antioxidants; (iv) patients with a stay in hospital ward prior to ICU admission longer than 24 h or transferred from another hospital; (v) surgical patients. Those patients in a post-cardiopulmonary resuscitation state or with suspected viral infection, as well as pregnant women and patients who did not provide consent, were excluded. Informed consent was obtained from all participants.

Regarding the focus of infection in sepsis and septic shock patients, cultures resulted positive for Gram-negative bacteria in 3 sepsis patients and 11 septic shock patients; Gram-positive bacteria were detected in 2 sepsis and 2 septic shock patients; and cultures resulted negative for 9 sepsis and 6 septic shock patients.

Appendix A.5. References

- 1 Shechter, D.; Dormann, H. L.; Allis, C. D. & Hake, S. B. Extraction, purification and analysis of histones. *Nature protocols* 2, 1445–1457, doi:10.1038/nprot.2007.202 (2007).
- 2 Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Analytical Biochemistry* 72, 248–254, doi:https://doi.org/10.1016/0003-2697(76)90527-3 (1976).

References

1. Singer, M.; Deutschman, C.S.; Seymour, C.C.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G.R.; Chiche, J.-D.; Coopersmith, C.C.; et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA* **2016**, *315*, 801–810, <https://doi.org/10.1001/jama.2016.0287>.
2. Joffre, J.; Hellman, J. Oxidative stress and endothelial dysfunction in sepsis and acute inflammation. *Antioxid. Redox Signal* **2021**, <https://doi.org/10.1089/ars.2021.0027>.
3. Beraha, E.M.; Salemink, E.; Goudriaan, A.E.; Bakker, A.; de Jong, D.; Smits, N.; Zwart, J.W.; van Geest, D.; Bodewits, P.; Schiphof, T.; et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial. *Eur. Neuropsychopharmacol.* **2016**, *26*, 1950–1959, <https://doi.org/10.1016/j.euroneuro.2016.10.006>.
4. Westwood, M.; Ramaekers, B.; Whiting, P.; Tomini, F.; Joore, M.; Armstrong, N.; Ryder, S.; Stirk, L.; Severens, J.; Kleijnen, J. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: A systematic review and cost-effectiveness analysis. *Heal. Technol. Assess.* **2015**, *19*, 1–236, <https://doi.org/10.3310/hta19960>.
5. de Jong, E.; van Oers, J.A.; Beishuizen, A.; Vos, P.; Vermeijden, W.J.; Haas, L.E.; Loeff, B.G.; Dormans, T.; van Melsen, G.C.; Kluiters, Y.C.; et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: A randomised, controlled, open-label trial. *Lancet Infect. Dis.* **2016**, *16*, 819–827, [https://doi.org/10.1016/s1473-3099\(16\)00053-0](https://doi.org/10.1016/s1473-3099(16)00053-0).
6. Struck, J.; Tao, C.; Morgenthaler, N.G.; Bergmann, A. Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients. *Peptides* **2004**, *25*, 1369–1372, <https://doi.org/10.1016/j.peptides.2004.06.019>.
7. Suberviola, B.; Castellanos-Ortega, A.; Llorca, J.; Ortiz, F.; Iglesias-Posadilla, D.; Prieto, B. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia. *Swiss Med. Wkly.* **2012**, *142*, w13542–w13542, <https://doi.org/10.4414/smww.2012.13542>.
8. Schuetz, P.; Christ-Crain, M.; Müller, B. Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. *Curr. Opin. Crit. Care* **2007**, *13*, 578–585, <https://doi.org/10.1097/mcc.0b013e3282c9ac2a>.
9. Silvestre, J.; Coelho, L.; Póvoa, P. Should C-reactive protein concentration at ICU discharge be used as a prognostic marker? *BMC Anesthesiol.* **2010**, *10*, 17–17, <https://doi.org/10.1186/1471-2253-10-17>.
10. Pierrakos, C.; Vincent, J.-L. Sepsis biomarkers: A review. *Crit. Care* **2010**, *14*, R15–R15, <https://doi.org/10.1186/cc8872>.
11. Silk, E.; Zhao, H.; Weng, H.; Ma, D. The role of extracellular histone in organ injury. *Cell Death Dis.* **2017**, *8*, e2812, <https://doi.org/10.1038/cddis.2017.52>.
12. Mena, H.A.; Carestia, A.; Scotti, L.; Parborell, F.; Schattner, M.; Negrotto, S. Extracellular histones reduce survival and angiogenic responses of late outgrowth progenitor and mature endothelial cells. *J. Thromb. Haemost.* **2016**, *14*, 397–410, <https://doi.org/10.1111/jth.13223>.

13. Pérez-Cremades, D.; Bueno-Beti, C.; García-Giménez, J.L.; Ibañez-Cabellos, J.S.; Hermenegildo, C.; Pallardó, F.V.; Novella, S. Extracellular histones disarrange vasoactive mediators release through a COX-NOS interaction in human endothelial cells. *J. Cell. Mol. Med.* **2017**, *21*, 1584–1592, <https://doi.org/10.1111/jcmm.13088>.
14. Raffray, L.; Douchet, I.; Augusto, J.-F.; Youssef, J.; Contin-Bordes, C.; Richez, C.; Duffau, P.; Truchetet, M.-E.; Moreau, J.-F.; Cazanave, C.; et al. Septic shock sera containing circulating histones induce dendritic cell-regulated necrosis in fatal septic shock patients. *Crit. Care Med.* **2015**, *43*, e107–e116, <https://doi.org/10.1097/ccm.0000000000000879>.
15. Xu, J.; Zhang, X.; Pelayo, R.; Monestier, M.; Ammollo, C.T.; Semeraro, F.; Taylor, F.B.; Esmon, N.L.; Lupu, F.; Esmon, C.T. Extracellular histones are major mediators of death in sepsis. *Nat. Med.* **2009**, *15*, 1318–1321, <https://doi.org/10.1038/nm.2053>.
16. Cabellos, J.S.I.; Aguado, C.; Pérez-Cremades, D.; García-Giménez, J.L.; Bueno-Beti, C.; García-López, E.M.; Romá-Mateo, C.; Novella, S.; Hermenegildo, C.; Pallardó, F.V. Extracellular histones activate autophagy and apoptosis via mTOR signaling in human endothelial cells. *Biochim. et Biophys. Acta (BBA) Mol. Basis Dis.* **2018**, *1864*, 3234–3246, <https://doi.org/10.1016/j.bbadis.2018.07.010>.
17. García Giménez, J.L.; Romá Mateo, C.; Seco Cervera, M.; Ibañez Cabellos, J.S.; Pallardó, F.V. Chapter 25—Circulating histones and nucleosomes as biomarkers in sepsis and septic shock A2—García-Giménez, José Luis. In *Epigenetic Biomarkers and Diagnostics*; Academic Press: Boston, MA, USA, 2016; <https://doi.org/10.1016/B978-0-12-801899-6.00025-5> pp. 497–517.
18. Wildhagen, K.C.; Wiewel, M.A.; Schultz, M.J.; Horn, J.; Schrijver, R.; Reutelingsperger, C.P.; van der Poll, T.; Nicolaes, G.A. Extracellular histone H3 levels are inversely correlated with antithrombin levels and platelet counts and are associated with mortality in sepsis patients. *Thromb. Res.* **2015**, *136*, 542–547, <https://doi.org/10.1016/j.thromres.2015.06.035>.
19. Yang, H.; Wang, H.; Chavan, S.S.; Andersson, U. High Mobility Group Box Protein 1 (HMGB1): The Prototypical Endogenous Danger Molecule. *Mol. Med.* **2015**, *21*, S6–S12, <https://doi.org/10.2119/molmed.2015.00087>.
20. Deng, M.; Tang, Y.; Li, W.; Wang, X.; Zhang, R.; Zhang, X.; Zhao, X.; Liu, J.; Tang, C.; Liu, Z.; et al. The Endotoxin delivery protein HMGB1 mediates caspase-11-dependent lethality in sepsis. *Immunity* **2018**, *49*, 740–753.e7, <https://doi.org/10.1016/j.immuni.2018.08.016>.
21. Zhou, Q.; Tu, T.; Tai, S.; Tang, L.; Yang, H.; Zhu, Z. Endothelial specific deletion of HMGB1 increases blood pressure and retards ischemia recovery through eNOS and ROS pathway in mice. *Redox Biol.* **2021**, *41*, 101890, <https://doi.org/10.1016/j.redox.2021.101890>.
22. García-Giménez, J.L.; Romá-Mateo, C.; Carbonell, N.; Palacios, L.; Peiró-Chova, L.; García-López, E.; García-Simón, M.; Lahuerta, R.; Gimenez-Garzó, C.; Berenguer-Pascual, E.; et al. A new mass spectrometry-based method for the quantification of histones in plasma from septic shock patients. *Sci. Rep.* **2017**, *7*, 1–10, <https://doi.org/10.1038/s41598-017-10830-z>.
23. Zeerleder, S.; Stephan, F.; Emonts, M.; De Kleijn, E.D.; Esmon, C.T.; Varadi, K.; Hack, C.E.; Hazelzet, J. Circulating nucleosomes and severity of illness in children suffering from meningococcal sepsis treated with protein C. *Crit. Care Med.* **2012**, *40*, 3224–3229, <https://doi.org/10.1097/ccm.0b013e318265695f>.
24. Li, Y.; Liu, Z.; Liu, B.; Zhao, T.; Chong, W.; Wang, Y.; Alam, H.B. Citrullinated histone H3: A novel target for the treatment of sepsis. *Surgery* **2014**, *156*, 229–234, <https://doi.org/10.1016/j.surg.2014.04.009>.
25. Alhamdi, Y.; Abrams, S.T.; Cheng, Z.; Jing, S.; Su, D.; Liu, Z.; Lane, S.M.; Welters, I.D.; Wang, G.; Toh, C.-H. Circulating histones are major mediators of cardiac injury in patients with sepsis. *Crit. Care Med.* **2015**, *43*, 2094–2103, <https://doi.org/10.1097/ccm.0000000000001162>.
26. Allam, R.; Kumar, S.V.; Darisipudi, M.N.; Anders, H.-J. Extracellular histones in tissue injury and inflammation. *J. Mol. Med.* **2014**, *92*, 465–472, <https://doi.org/10.1007/s00109-014-1148-z>.
27. Szatmary, P.; Huang, W.; Criddle, D.; Tepikin, A.; Sutton, R. Biology, role and therapeutic potential of circulating histones in acute inflammatory disorders. *J. Cell. Mol. Med.* **2018**, *22*, 4617–4629, <https://doi.org/10.1111/jcmm.13797>.
28. Deng, M.; Scott, M.J.; Fan, J.; Billiar, T.R. Location is the key to function: HMGB1 in sepsis and trauma-induced inflammation. *J. Leukoc. Biol.* **2019**, *106*, 161–169, <https://doi.org/10.1002/JLB.3MIR1218-497R>.
29. Rudd, K.E.; Johnson, S.C.; Agesa, K.M.; Shackelford, K.A.; Tsoi, D.; Kievian, D.R.; Colombara, D.V.; Ikuta, K.; Kisson, N.; Finfer, S.; et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: Analysis for the Global Burden of Disease Study. *Lancet* **2020**, *395*, 200–211, [https://doi.org/10.1016/s0140-6736\(19\)32989-7](https://doi.org/10.1016/s0140-6736(19)32989-7).
30. Chen, Q.; Ye, L.; Jin, Y.; Zhang, N.; Lou, T.; Qiu, Z.; Jin, Y.; Cheng, B.; Fang, X. Circulating nucleosomes as a predictor of sepsis and organ dysfunction in critically ill patients. *Int. J. Infect. Dis.* **2012**, *16*, e558–e564, <https://doi.org/10.1016/j.ijid.2012.03.007>.
31. Beltrán-García, J.; Osca-Verdegai, R.; Romá-Mateo, C.; Carbonell, N.; Ferreres, J.; Rodríguez, M.; Mulet, S.; García-López, E.; Pallardó, F.V.; García-Giménez, J.L. Epigenetic biomarkers for human sepsis and septic shock: Insights from immunosuppression. *Epigenomics* **2020**, *12*, 617–646, <https://doi.org/10.2217/epi-2019-0329>.
32. Basso, D.; Padoan, A.; Laufer, T.; Aneloni, V.; Moz, S.; Schroers, H.; Pelloso, M.; Saiz, A.; Krapp, M.; Fogar, P.; et al. Relevance of pre-analytical blood management on the emerging cardiovascular protein biomarkers TWEAK and HMGB1 and on miRNA serum and plasma profiling. *Clin. Biochem.* **2016**, *50*, 186–193, <https://doi.org/10.1016/j.clinbiochem.2016.11.005>.
33. Le, K.; Mo, S.; Lu, X.; Ali, A.I.; Yu, D.; Guo, Y. Association of circulating blood HMGB1 levels with ischemic stroke: A systematic review and meta-analysis. *Neurol. Res.* **2018**, *40*, 907–916, <https://doi.org/10.1080/01616412.2018.1497254>.
34. Liu, Y.; Zhou, C.; Jiang, J.; Su, Q.; Ding, X. Blockade of HMGB1 preserves vascular homeostasis and improves blood perfusion in rats of acute limb ischemia/reperfusion. *Microvasc. Res.* **2017**, *112*, 37–40, <https://doi.org/10.1016/j.mvr.2017.02.005>.
35. Karlsson, S.; Pettilä, V.; Tenhunen, J.; Laru-Sompa, R.; Hynninen, M.; Ruokonen, E. HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. *Intensiv. Care Med.* **2008**, *34*, 1046–1053, <https://doi.org/10.1007/s00134-008-1032-9>.